Suven Life Sciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
SUVEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Suven Life Sciences reported standalone revenue from operations of Rs. 711.47 lakhs for FY2026, up 6.9% from Rs. 665.58 lakhs in FY2025. However, the company reported a significantly widened standalone net loss of Rs. 5,486.28 lakhs compared to Rs. 4,707.98 lakhs loss in the previous year. On a consolidated basis, losses are much larger at Rs. 27,634.41 lakhs due to the US subsidiary Suven Neurosciences Inc., which incurred R&D expenses of Rs. 24,818.81 lakhs and a net loss of Rs. 22,148.12 lakhs. The company raised Rs. 76,432.53 lakhs through a preferential issue of convertible warrants, with Rs. 26,068.64 lakhs utilized so far. Operating cash flows remained deeply negative at Rs. 6,959.79 lakhs on standalone basis. The auditors issued unmodified opinions on both standalone and consolidated financials.
The stock is likely to face selling pressure due to significantly widened losses driven by heavy R&D spending, though the company has substantial cash reserves from warrant issuances to fund operations. The negative operating cash flows and ongoing losses raise concerns about sustainability without continued capital raises.